Wales may receive less corornavirus vaccine than anticipated over the next few weeks which could affect the mid-April target, the health minister has admitted.
Vaughan Gething, speaking at the Welsh Government’s press conference on Wednesday, said there was a “potential gap” in some of the supply which means Wales could get “less than expected”.
Latest figures show that 1,857,590 doses of Covid-19 vaccine have been allocated to Wales but 1,523,290 doses have been delivered, leaving a shortfall of 334,300. This data includes both the Pfizer BioNTech and Oxford AstraZeneca doses.
The current target in Wales is for all those in priority groups one to nine to be offered the vaccine by the middle of April.
“We do understand there’s a potential gap in some of the supplies coming forward – we may get less than expected,” admitted Mr Gething, answering a question from Rob Taylor at Wrexham.com.
“But we are still working that through and I will be talking about that with health ministers in the four nations meeting this week, as well as the UK minister for vaccine supply.
“We need to be clear about that means [and whether it will] impact on the mid-April milestone.”
Mr Gething did stress, however, that the vaccination programme was continuing at pace in Wales and was “in really good shape”, with latest data showing that 1,157,251 people have now received a first dose and a further 289,185 have had both jabs.
Uptake of the first vaccine dose by priority group (according to PHW):
- Care home residents: 13,183 (95.7%)
- Care home workers: 32,270 (85.8%)
- Healthcare workers: 126,240 (89.1%)
- Social care workers: 40,729
- 80 years and older: 166,302 (94.6%)
- 75-79 years: 126,865 (95.1%)
- 70-74 years: 173,576 (94.5%)
- Clinically extremely vulnerable 16-69 years: 73,032 (89.7%)
- 65-69 years: 164,540 (91.3%)
- Clinical risk groups 16-64 years: 189,489 (55.4%)
- 60-64 years: 127,982 (62.4%)
- 55-59 years: 87,778 (37.7%)
- 50-54 years: 73,260 (32.2%)
Meanwhile, the Welsh Government figures show that up to March 14, just 0.5% of vaccine doses were reported as “not suitable for use” and were therefore wasted.
Split by vaccine type, 1% of Pfizer BioNTech and 0.1% of Oxford AstraZeneca vaccine doses were reported as not suitable for use.